ArticleCancer medicine2026
Cardiovascular Disease Mortality Patterns Among People With Cancer in New South Wales, Australia: A Population-Wide Data Linkage Study.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate cardiovascular disease (CVD) mortality patterns among people with cancer in New South Wales (NSW) compared to the NSW general population and trends over time.
designPopulation-wide retrospective data-linkage study. PARTICIPANTS AND
setting873,344 people aged ≥ 40 diagnosed with primary invasive cancer and registered in the NSW Cancer Registry between 1985 and 2019. MAIN OUTCOMES: CVD as the underlying cause of death. Absolute mortality rate (AMR, per 10,000 person-years) and standardised mortality ratios (SMR) compared to the NSW general population.
resultsOf 514,865 people with cancer who died between 1985 and 2020, 71% (n = 303,770) died from cancer and while 14% (n = 73,733) from CVD. AMR of CVD increased with time since cancer diagnosis (≤ 2 years: AMR = 124 vs. > 10 years: AMR = 152) and declined from 188 in 1985-1995 to 68 in 2010-2020 following cancer diagnosis in 1985-1989 and 2010-2014, respectively. Approximately 45% of CVD deaths were due to ischaemic heart disease, with 49% in males versus 40% in females. Elevated SMRs of CVD were found for ≤ 2 years after cancer diagnosis (SMR = 1.17, 95% CI: 1.15, 1.19), those aged 40-59 (SMR = 1.13, 95% CI: 1.07, 1.19) and those diagnosed with distant metastases (SMR = 1.31, 95% CI: 1.27, 1.35) or lung cancer (SMR = 1.42, 95% CI: 1.37, 1.47). Lower CVD SMRs were observed for > 2 years after cancer diagnosis (e.g., for 2-5 years: SMR = 0.84, 95% CI: 0.83, 0.86), among people diagnosed with cancers with higher survival rates (e.g., Melanoma: SMR = 0.79, 95% CI: 0.78, 0.81) and in the most recent period 2010-2020 (SMR = 0.85, 95% CI: 0.83, 0.87).
conclusionHigher than expected CVD mortality compared to the general population was observed within the first few years after cancer diagnosis, especially among those diagnosed with lung cancer and distant metastases, which might reflect shared risk factors and cardiotoxic treatment. Our findings underscore the need for CVD risk assessment, prevention, and care among people with cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.